Damage or loss of brain cells and impaired neurochemistry, neurogenesis, and synaptic and
nonsynaptic plasticity of the brain lead to dementia in neurodegenerative diseases, such as …

In June 2021, the world was informed about a new drug for Alzheimer's disease approved
by the FDA. Aducanumab (BIIB037, ADU), being a monoclonal antibody IgG1, is the newest …

Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …

Combining existing drug therapy is essential in developing new therapeutic agents in
disease prevention and treatment. In preclinical investigations, combined effect of certain …

Alzheimer's disease (AD), as a neurodegenerative disorder, usually develops slowly but
gradually worsens. It accounts for approximately 70% of dementia cases worldwide, and is …

Alzheimer's disease (AD) represents the most common form of dementia, characterized by
amyloid β (Aβ) plaques and neurofibrillary tangles (NFTs). It is characterized by …

Alzheimer's disease (AD) is a neurodegenerative disease, characterized by memory loss
and cognitive deficits accompanied by neuronal damage and cholinergic disorders …

Alzheimer's disease (AD) is the primary cause of dementia and is characterized by the death
of brain cells due to the accumulation of insoluble amyloid plaques, hyperphosphorylation of …

Alzheimer's disease (AD) has a complex and not-fully-understood etiology. Recently, the
serotonin receptor 5-HT6 emerged as a promising target for AD treatment; thus, here a new …

Evidence suggests that increased level/aggregation of β-amyloid (Aβ) peptide, together with
enhanced phosphorylation/aggregation of tau protein, play a critical role in the development …